

# EVALUATION ADVISORY COMMITTEE CHAIR REPORT

BOARD MEETING

James Hargreaves

1-2 July 2026, Geneva, Switzerland

# Overarching Issues and Guidance

## **Gavi 5.1 Evaluation Workplan Close-Out**

Guidance on close-out of Gavi 5.0 evaluation workplan and key Gavi 5.1 evaluations: COVAX and zero-dose phase 2

## **Gavi 6.0 Evaluation Workplan**

Guidance on critical touchpoints to streamline processes, reduce transaction costs on relevant teams, timing shift for AVMA Evaluability Assessment and opportunities to strengthen evaluation processes given stakeholders' reduced availability

## **Evaluation Policy Revision and Interim Ways of Working**

Guidance on the approval pathway for policy revision and interim operational ways of working for the evaluation function in 2026

## **Collaboration with the Global Fund**

Principles and areas for evaluation collaboration between Gavi and the Global Fund

# Gavi 5.1 Evaluation Workplan close-out and use of evaluation

## Gavi 5.0 evaluation workplan close-Out

Committee updated on close-out of 5.0 workplan and design of MEL 6.0

MEL 6.0 introduces a more integrated and adaptive approach to evidence generation, learning, and performance management

EAC highlighted the critical role of evaluation in identifying blind spots and addressing evidence gaps

EAC noted importance of evaluation in a constrained resource environment

## Key Evaluations Closed

**Joint COVAX Evaluation Closed** — dissemination and follow-up ongoing



Published on Gavi website: see link [here](#)

**ZD phase 2 evaluation**

**Closed** — dissemination complete and follow-up actions ongoing

**Annual Evaluation Report (2025) published:**

See link [here](#)



## USE:

The Evaluation of Gavi's contribution to reaching ZD children and missed communities findings contributed evidence to and informed the consolidation of Gavi funding levers into a single grant mechanism for all cash and TA support, reducing fragmentation and improving coherence across grant investments.

The joint COVAX evaluation phase 2 findings – specifically, that future pandemic response mechanisms should adopt a multilateral approach to ensuring equitable access to vaccines – continue to inform the operationalisation of the interim Medical Countermeasures Net (i-MCMnet) and the recently adopted WHO Pandemic Agreement.

# Gavi 6.0 Evaluation Workplan

## In progress

### Big Catch Up (BCU) Evaluation

Inception phase complete  
Implementation underway  
Final report expected in early Q4

## In progress

### Private Sector Engagement (PSE) Strategy

Inception phase complete  
Implementation underway  
Draft report due July 2026 — to inform Gavi 6.0 PSE strategy

### AVMA Evaluability Assessment

Timeline shifted to Q3/Q4 2026, pending further governance guidance — endorsed by the EAC

**Grant Management Reform and Malaria evaluations:** scoping of learning questions and planning for the Evaluability Assessments underway

The EAC endorsed the prioritisation of evaluation touchpoints as indicated to streamline the process, including enhancing country engagement as appropriate to the evaluation purpose/scope and considering efficient ways to include partners at specific touchpoints.

EAC emphasised the importance of follow up of evaluation management response actions with Alliance Partners. Support including language that strengthens partner engagement in evaluations within grant agreements.

EAC advised the Secretariat to seek opportunities in the new working environment to strengthen evaluation, for example drawing on a broader range of evaluation forms.

# Gavi 6.0 Costed Evaluation Workplan

|                                                                         | Evaluations                                                                                                                                                                                                                                                                                                                                                                              | Proposed year evaluation is delivered<br>(& key use case)                                                                           | Budget                             |
|-------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| <b>A</b><br>Continued programmes from 5.1                               | 1. Vaccine Delivery Platforms: Malaria<br>2. Big Catch-Up<br>3. Gavi 5.0's board-approved Private Sector and Innovation strategy                                                                                                                                                                                                                                                         | 2027 (6.0 course-correction & 7.0 design)<br>2026 (6.0 course-correction & 7.0 design)<br>2026 (6.0 course-correction & 7.0 design) | 500K<br>US\$399.056<br>US\$345.090 |
| <b>B</b><br>Programmatic shifts in 6.0                                  | 5. Approach to Fragile and Humanitarian Settings 6.0                                                                                                                                                                                                                                                                                                                                     | 2029 (7.0 operationalisation)                                                                                                       | 0.5-1m                             |
| <b>C</b><br>GMR: shifts to funding model and grant management processes | . Gavi 6.0 shifts to:<br>a) <u>funding model</u> (country vaccine budgets, VPOP, campaigns, ELTRACO, HSS policy, MDB multiplier, domestic financing, partnership approach inc. collaboration under Lusaka Agenda); and<br>b) <u>grant management processes</u> (grant cycle alignment, simplification e.g. single application, differentiated approach to grant design,)<br>(Two phases) | Phase 1: 2027 (Mid-Term Review, 7.0 design)<br>Phase 2: 2029 (7.0 operationalisation)                                               | 2-3.5m                             |
| <b>D</b><br>AVMA                                                        | 7. Evaluability Assessment of the African Vaccine Manufacturing Accelerator (AVMA)                                                                                                                                                                                                                                                                                                       | 2026 (AVMA MEL Framework and endline evaluation)                                                                                    | 100k                               |
| <div> <div>←</div> <div>EVALUABILITY (300K)</div> <div>→</div> </div>   |                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                     |                                    |

# Evaluation policy revision and interim ways of working

## Evaluation Policy revision

*EAC approval pathway requirements:*

- Early and continuous EAC engagement throughout the process
- Co-creation of both the policy and the approval pathway
- Greater clarity on EAC's oversight/advisory role

## Interim ways of working (WOW) 2026

*Adaptations reflecting resource constraints:*

- Increased outsourcing of quality assurance
- Adapted steering committee arrangements
- More streamlined engagement models and meeting formats

*EAC supports these adaptations while underlining the need to maintain evaluation independence, quality, and is supportive of ways of working (WoW) shifts proposed, but notes that they represent a meaningful shift in WOW and to keep under review.*

# Gavi–Global Fund Collaboration

## *EAC Guidance on Proposed Collaboration Principles*

### **Build on existing findings**

The EAC supported joint learning on Global Fund ELO Audit and Gavi Evaluation Function Review (EFR) findings and advised to define collaboration with greater clarity and specificity

### **Apply useful principles**

Ensure collaboration is guided by clear, agreed principles relevant to both organisations' evaluation mandates

### **Clear value add**

Activities must demonstrate clear value-add and feasibility and avoid overlap or duplication of effort

### **Joint evaluations**

Consider the value-add of Joint Evaluations where relevant, as opportunities mature

Completion of the Gavi-Global Fund Task force assessment of evaluation functions was noted and the EAC supports continued ongoing collaboration and shared learning. *Evaluation-specific collaboration is not currently prioritised — Gavi may proceed with its own policy and process reforms while exploring opportunities as they mature.*

# Thank you

# Progress update – decentralised evaluations

| Decentralised Evaluation                                                                                                                                                                                                        | Team | Timeline  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| Development, Implementation, Monitoring and Evaluation of a National and/or Subnational Advocacy Strategy for Increased PHC and Immunisation Financing                                                                          | IF&S | 2022–2026 |
| Design, Implementation, Monitoring, Evaluation and Learning of Country Specific DSI (Conditional Cash or Non-Cash Transfers) for Increasing Demand for Vaccinations, Increasing Coverage and Reducing the Number of ZD Children | IF&S | 2023–2026 |
| DHI Roadmap Assessments (costed DHI roadmap studies)                                                                                                                                                                            | HSIS | 2023–2026 |
| Evaluation of Gavi’s DHI Strategy                                                                                                                                                                                               | HSIS | 2023–2026 |
| Evaluation of the Niger Direct Financing Facility                                                                                                                                                                               | IF&S | 2023–2026 |
| Evaluation of the Djibouti Direct Facility Financing (DFF) and Performance-Based Financing (PBF)                                                                                                                                | IF&S | 2023–2026 |
| Evaluation of the Clinton Health Access Initiative (CHAI) Collaborative Learning Strategic Focus Area (SFA)                                                                                                                     | IF&S | 2024–2026 |
| Afghanistan Unconditional Cash Transfers Plus Programme Evaluation                                                                                                                                                              | IF&S | 2024–2026 |
| Gender Evaluation                                                                                                                                                                                                               | HSIS | 2026      |
| Evaluation of HFSE-CCEOP Learning Agenda                                                                                                                                                                                        | HSIS | 2025-2026 |
| Demand Process Evaluation                                                                                                                                                                                                       | HSIS | 2026      |

Note: As per last update from Gavi teams, Jan 2026. For more info: Annual Evaluation Report 2025